Argent BioPharma Limited (ASX:RGT)
Australia · Delayed Price · Currency is AUD 0.0320
+0.0020 (6.67%)
Sep 4, 2026, 3:58 PM AEST
Argent BioPharma Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 0.16 | 0.18 | 0.89 | 3.39 | 4.73 | |
Revenue Growth | -10.73% | -79.74% | -73.69% | -28.41% | 57.94% |
Cost of Revenue | 0.2 | 0.78 | 1.2 | 2.04 | 4.17 |
Gross Profit | -0.04 | -0.6 | -0.3 | 1.35 | 0.56 |
Selling, General & Admin | 6.86 | 12.12 | 15.56 | 13.34 | 11.83 |
Research & Development | 0.49 | 3.59 | 2.32 | 2.99 | - |
Other Operating Expenses | 0.03 | -0.67 | -0.16 | 0.22 | 4.23 |
Operating Expenses | 7.4 | 15.04 | 17.72 | 16.56 | 16.06 |
Operating Income | -7.44 | -15.64 | -18.02 | -15.21 | -15.5 |
Interest Expense | -0.03 | -0.05 | -0.48 | -0.26 | -0.21 |
Interest & Investment Income | - | 0 | 0 | 0 | 0 |
Earnings From Equity Investments | 0.01 | - | - | - | - |
Currency Exchange Gain (Loss) | 0.41 | 0.36 | 0.83 | -1.22 | 0.08 |
Other Non Operating Income (Expenses) | -0.6 | - | 0.06 | 0.09 | -1.24 |
EBT Excluding Unusual Items | -7.65 | -15.33 | -17.61 | -16.6 | -16.86 |
Impairment of Goodwill | - | - | - | -3.15 | -3.9 |
Gain (Loss) on Sale of Investments | - | -1.41 | 1.34 | -1.39 | - |
Gain (Loss) on Sale of Assets | -0.06 | -0.12 | -0.02 | - | - |
Asset Writedown | - | -0.98 | -1.26 | - | - |
Pretax Income | -7.71 | -17.84 | -17.55 | -21.13 | -20.77 |
Income Tax Expense | - | - | - | 0 | - |
Earnings From Continuing Operations | -7.71 | -17.84 | -17.55 | -21.13 | -20.77 |
Net Income to Company | -7.71 | -17.84 | -17.55 | -21.13 | -20.77 |
Minority Interest in Earnings | - | - | 0.02 | 0.31 | 0.42 |
Net Income | -7.71 | -17.84 | -17.53 | -20.82 | -20.35 |
Net Income to Common | -7.71 | -17.84 | -17.53 | -20.82 | -20.35 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 87 | 57 | 37 | 3 | 3 |
Shares Outstanding (Diluted) | 87 | 57 | 37 | 3 | 3 |
Shares Change | 51.69% | 54.47% | 1155.86% | 14.85% | 34.63% |
EPS (Basic) | -0.09 | -0.31 | -0.47 | -7.07 | -7.93 |
EPS (Diluted) | -0.09 | -0.31 | -0.47 | -7.10 | -7.93 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -4.03 | -9.28 | -14.8 | -12.18 | -14.85 |
Free Cash Flow Per Share | -0.05 | -0.16 | -0.40 | -4.13 | -5.79 |
Gross Margin | -24.58% | - | -34.13% | 39.88% | 11.89% |
Operating Margin | -4617.46% | -8663.31% | -2022.52% | -448.91% | -327.54% |
Profit Margin | -4783.36% | -9882.48% | -1967.34% | -614.71% | -430.00% |
Free Cash Flow Margin | -2498.15% | -5140.45% | -1661.19% | -359.40% | -313.85% |
EBITDA | -7.4 | -15.08 | -16.95 | -14.67 | -15.4 |
D&A For EBITDA | 0.05 | 0.56 | 1.08 | 0.54 | 0.1 |
EBIT | -7.44 | -15.64 | -18.02 | -15.21 | -15.5 |